1. South Korea Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Hans Biomed Corp

Hans Biomed Corp

KKRX:042520
17,960.00
KRW
-150.00
(-0.83%)
-1,917.53EPS
480.61BMarket Cap
Dec 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2,431.38
2,297.23
2,486.27
3,083.69
4,146.23
5,368.82
6,813.11
8,117.51
5,903.81
7,558.45
7,280.16
6,268.19
6,913.07
8,243.32
Basic EPS, GAAP
417
382
521
491
831
431.56
1,012
-1,808
-1,827
624
-2,150
-558
-2,413.29
-1,853.68
Free Cash Flow per Basic Share
-735.49
-1,211.52
-276.49
-1,064.63
-935.24
179.05
-916.17
-345.12
-1,983.22
-853.07
-541.08
-82.7
-110.82
-1,690.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3,456.42
4,182.65
4,582.84
4,971.46
5,705.35
6,646.77
7,592.23
6,026.47
4,439.82
4,732.03
4,243.81
5,149.32
2,595.2
5,203.85
Tangible Book Value per Share
3,106.23
3,813.92
4,127.95
4,427.35
5,204.87
6,396.29
6,594.4
5,667.21
4,327.93
4,638.72
4,178.52
5,088.1
2,553.95
5,168.71
Basic Weighted Avg Shares
8
9
9
9
9
10
10
10
10
10
11
13
13
13
Sales/Revenue/Turnover
20,066
21,033
23,428
29,048
39,058
51,746
66,991
80,098
59,098
74,459
78,032
81,137
89,780
110,500
Operating Margin (%)
19.45
18.57
21.59
20.62
24.22
20.21
18.8
-4.25
-33.47
1.74
-5.32
0.77
-28.84
-18.47
Depreciation Expense
798
636
839
1,101
1,646
1,880
1,754
3,613
4,785
4,902
5,198
5,386
5,112
4,737
Net Income, GAAP
3,441
3,498
4,909
4,625
7,828
4,159
9,951
-17,840
-18,289
6,147
-23,045
-7,223
-31,341
-24,848
Effective Tax Rate (%)
12.57
11.4
11.07
13.59
18.08
7.1
17.18
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
17.15
16.63
20.96
15.92
20.04
8.04
14.85
-22.27
-30.95
8.26
-29.53
-8.9
-34.91
-22.49
Working Capital
13,578
12,607
12,996
11,312
4,125
17,160
34,609
30,604
-9,878
-20,072
-14,860
-385
-24,963
15,144
LT Debt
- -
- -
588
3,000
- -
- -
23,597
22,699
14,536
1,347
749
1,000
7,199
7,078
Total Equity
29,309
39,390
43,158
47,512
55,023
69,541
84,070
69,299
47,581
47,455
49,949
67,122
33,887
73,977
Return on Invested Capital (%)
12.72
9.82
10.23
9.74
11.5
12.15
10.27
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
12.9
10.18
11.41
8.48
11.53
4.54
10.94
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
12.9
10.18
11.89
10.28
15.57
6.99
14.2
-26.39
-34.91
13.65
-48.64
-12.45
-62.32
-35.62

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
36,107
36,095
35,148
LT Borrowings
6,000
6,000
6,000
LT Finance Leases
1,199
1,077
1,078
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
14
14
Market Capitalization
235,973
393,062
480,608

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
56,072
70,655
77,773
Cash, Cash Equivalents & STI
8,149
15,917
17,954
Accounts Receivable, Net
16,646
19,714
23,187
Inventories
28,833
29,688
29,400
Total Current Liabilities
81,034
60,840
62,629
Payables & Accruals
- -
- -
- -
ST Debt
36,107
36,095
35,148
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.41%
-8.3%
-49.52%
Free Cash Flow
-18.38%
69.44%
34.45%
Net Income, GAAP
-46.42%
-68.15%
333.91%
Sales/Revenue/Turnover
15.92%
3.84%
10.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20,360
20,453
20,814
19,510
81,137
2025
19,876
24,155
22,034
23,715
89,780
2026
30,266
34,486
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-79.2
-4
7
-480.63
-558
2025
-142
64
-250.38
-2,126.42
-2,413.29
2026
153.53
277.99
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Geun-Young Kim
Full Time Employees
289
Sector
Health services
Industry
Medical/Nursing services
Address
Seoul South Korea
IPO Date
Oct 22, 2009
Website
hansbiomed.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Hans Biomed Corp. is a South Korea-based biotechnology and medical device company that develops, manufactures, and commercializes advanced tissue engineering, regenerative medicine, and aesthetic medical solutions. Founded in 1999 and headquartered in Seoul, South Korea, the company operates South Korea's first government-authorized tissue bank and serves plastic surgeons, dermatologists, orthopedic specialists, and dental practitioners across domestic and global markets. Hans Biomed structures its operations around three principal product and service divisions: Medical Aesthetics, Tissue Regeneration, and Surgical Healthcare. The company's portfolio comprises aesthetic lifting and rejuvenation systems, including MINT Lift polydioxanone (PDO) biodegradable facial lifting threads and CellREDM extracellular matrix (ECM)-based injectable skin boosters; silicone breast implants marketed under the Bellagel brand; biological tissue grafts, including SureDerm acellular dermal matrix (ADM) for soft tissue reconstruction and plastic surgery, alongside demineralized bone matrix (DBM) and synthetic bone graft substitutes for orthopedic and dental applications; and specialized surgical instruments and post-operative care solutions, featuring Lion Hair Transplanter devices and Scar Clinic silicone-based scar management sheets and gels. Hans Biomed distributes its products internationally across North America, Europe, Latin America, and the Asia-Pacific region, supported by overseas subsidiaries and branches in the United States, China, Thailand, Mexico, Colombia, and the United Kingdom, alongside the Levos joint venture in China. In recent corporate developments, Hans Biomed entered into a domestic commercialization partnership with Hugel Inc. to distribute its CellREDM skin booster across aesthetic medical clinics, increased its strategic equity stake in biotechnology firm A-Tems to support Phase 2 clinical trials for the knee cartilage regenerative therapeutic candidate A-Paste-C, and expanded international regulatory approvals and distribution agreements for its flagship MINT Lift aesthetic product line.